B+
Bull case
0%
Probability
Target price
$34.00
Analysis reference price unavailable
Analysis 2026-06-30 · RankAlpha Sentiment Codex
ARQT
Arcutis BiotherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
0%
Probability
Target price
$28.00
Analysis reference price unavailable
Analysis 2026-06-30 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$20.00
Analysis reference price unavailable
Analysis 2026-06-30 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-06-30
Recent news sentiment (30D)
+0.5
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+81.1
Score
AI commentary
Headline tone improved with the June 29, 2026 FDA approval for pediatric psoriasis, but the memo remains a tentative monitoring view rather than a standard-conviction thesis. The packet's deterministic prior is negative across 5d to 120d horizons, analyst-target breadth is unavailable, social context is absent, and peer read-through is loose. The next validation points are whether pediatric label expansion and sales-force investment convert into durable ZORYVE demand, gross-to-net stability, and operating leverage rather than a one-day regulatory headline.
RankAlpha Sentiment Codex - 2026-06-30
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-29eventFDA approved pediatric plaque-psoriasis label expansion for ZORYVE cream 0.3%High impact
Arcutis announced on June 29, 2026 that FDA approved ZORYVE cream 0.3% for plaque psoriasis in children as young as age 2, extending the franchise into a younger pediatric cohort and adding a fresh commercial launch vector [#IR-2026-06-29].
2026-12-15catalystPipeline readouts beyond the core franchise can widen or cap the multipleHigh impact
Management said Phase 2 proof-of-concept data for vitiligo are expected in Q4 2026 and hidradenitis suppurativa in Q1 2027, while ARQ-234 has entered Phase 1a/1b; these programs matter for proving Arcutis is more than a single-franchise commercial story [#PR-EARNINGS-2026-05-07].
2026-12-31catalystCommercial execution against 2026 revenue guidance remains the core value driverHigh impact
Q1 2026 net product revenue was $105.4M, up 65% year over year, and management maintained 2026 net product revenue guidance of $480M-$495M while noting completed dermatology sales-force expansion, primary-care/pediatrics build-out, and positive operating cash flow; however Q1 sales were down 17% sequentially due to deductible resets and insurance changes [#PR-EARNINGS-2026-05-07].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-30 • Updated nightlySource: Internal modelMethodology